CorMedix Inc. (CRMD)
NASDAQ: CRMD · Real-Time Price · USD
9.10
-0.05 (-0.55%)
Apr 25, 2025, 4:00 PM EDT - Market closed

CorMedix Statistics

Total Valuation

CorMedix has a market cap or net worth of $593.15 million. The enterprise value is $543.94 million.

Market Cap 593.15M
Enterprise Value 543.94M

Important Dates

The next estimated earnings date is Thursday, May 8, 2025, before market open.

Earnings Date May 8, 2025
Ex-Dividend Date n/a

Share Statistics

CorMedix has 65.18 million shares outstanding. The number of shares has increased by 15.66% in one year.

Current Share Class 65.18M
Shares Outstanding 65.18M
Shares Change (YoY) +15.66%
Shares Change (QoQ) +4.56%
Owned by Insiders (%) 6.58%
Owned by Institutions (%) 36.17%
Float 60.89M

Valuation Ratios

PE Ratio n/a
Forward PE 13.35
PS Ratio 12.39
Forward PS 4.13
PB Ratio 6.96
P/TBV Ratio 7.19
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 12.51
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 3.39, with a Debt / Equity ratio of 0.01.

Current Ratio 3.39
Quick Ratio 3.05
Debt / Equity 0.01
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -614.10

Financial Efficiency

Return on equity (ROE) is -23.17% and return on invested capital (ROIC) is -17.92%.

Return on Equity (ROE) -23.17%
Return on Assets (ROA) -13.91%
Return on Invested Capital (ROIC) -17.92%
Return on Capital Employed (ROCE) -26.30%
Revenue Per Employee $668,803
Profits Per Employee -$275,846
Employee Count 65
Asset Turnover 0.43
Inventory Turnover 0.66

Taxes

Income Tax -1.39M
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +70.73% in the last 52 weeks. The beta is 1.57, so CorMedix's price volatility has been higher than the market average.

Beta (5Y) 1.57
52-Week Price Change +70.73%
50-Day Moving Average 8.95
200-Day Moving Average 8.56
Relative Strength Index (RSI) 62.23
Average Volume (20 Days) 1,574,441

Short Selling Information

The latest short interest is 7.92 million, so 12.16% of the outstanding shares have been sold short.

Short Interest 7.92M
Short Previous Month 8.18M
Short % of Shares Out 12.16%
Short % of Float 13.01%
Short Ratio (days to cover) 3.97

Income Statement

In the last 12 months, CorMedix had revenue of $43.47 million and -$17.93 million in losses. Loss per share was -$0.30.

Revenue 43.47M
Gross Profit 40.28M
Operating Income -22.36M
Pretax Income n/a
Net Income -17.93M
EBITDA -22.05M
EBIT -22.36M
Loss Per Share -$0.30
Full Income Statement

Balance Sheet

The company has $51.69 million in cash and $517,013 in debt, giving a net cash position of $51.17 million or $0.79 per share.

Cash & Cash Equivalents 51.69M
Total Debt 517,013
Net Cash 51.17M
Net Cash Per Share $0.79
Equity (Book Value) 84.66M
Book Value Per Share 1.31
Working Capital 80.74M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$50.61 million and capital expenditures -$115,730, giving a free cash flow of -$50.73 million.

Operating Cash Flow -50.61M
Capital Expenditures -115,730
Free Cash Flow -50.73M
FCF Per Share -$0.78
Full Cash Flow Statement

Margins

Gross margin is 92.66%, with operating and profit margins of -51.43% and -41.24%.

Gross Margin 92.66%
Operating Margin -51.43%
Pretax Margin -44.45%
Profit Margin -41.24%
EBITDA Margin -50.71%
EBIT Margin -51.43%
FCF Margin n/a

Dividends & Yields

CorMedix does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -15.66%
Shareholder Yield -15.66%
Earnings Yield -3.01%
FCF Yield -8.52%

Analyst Forecast

The average price target for CorMedix is $14.50, which is 59.34% higher than the current price. The consensus rating is "Strong Buy".

Price Target $14.50
Price Target Difference 59.34%
Analyst Consensus Strong Buy
Analyst Count 6
Revenue Growth Forecast (5Y) 46.41%
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Stock Splits

The last stock split was on March 26, 2019. It was a reverse split with a ratio of 0.2:1.

Last Split Date Mar 26, 2019
Split Type Reverse
Split Ratio 0.2:1

Scores

CorMedix has an Altman Z-Score of 2.58. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score 2.58
Piotroski F-Score n/a